BMC Clinical Pathology | |
Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem | |
Matthew D Krasowski1  Jeff Kulhavy1  Scott R Davis1  Tami Bebber1  Denny Drees1  Cory S Morris1  Carolyn D Rysgaard1  | |
[1] Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, 52242, USA | |
关键词: Vaccination; Renal dialysis; Public health; Hepatitis B surface antigens; Hepatitis; False positive reactions; | |
Others : 1085325 DOI : 10.1186/1472-6890-12-15 |
|
received in 2012-04-23, accepted in 2012-09-22, 发布年份 2012 | |
【 摘 要 】
Background
Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients. However, the time course and duration of this effect is unclear. The objective of this retrospective study was to clarify the frequency and duration of transient HBsAg positivity following vaccination against HBV.
Methods
The electronic medical record at an academic tertiary care medical center was searched to identify all orders for HBsAg within a 17 month time period. Detailed chart review was performed to identify all patients who were administered HBV vaccine within 180 days prior to HBsAg testing and also to ascertain likely cause of weakly positive (grayzone) results.
Results
During the 17 month study period, 11,719 HBsAg tests were ordered on 9,930 patients. There were 34 tests performed on 34 patients who received HBV vaccine 14 days or less prior to HBsAg testing. Of these 34 patients, 11 had grayzone results for HBsAg that could be attributed to recent vaccination. Ten of the 11 patients were renal dialysis patients who were receiving HBsAg testing as part of routine and ongoing monitoring. Beyond 14 days, there were no reactive or grayzone HBsAg tests that could be attributed to recent HBV vaccination. HBsAg results reached a peak COI two to three days following vaccination before decaying. Further analysis of all the grayzone results within the 17 month study period (43 results out of 11,719 tests) revealed that only 4 of 43 were the result of true HBV infection as verified by confirmatory testing.
Conclusions
Our study confirms that transient HBsAg positivity can occur in patients following HBV vaccination. The results suggest this positivity is unlikely to persist beyond 14 days post-vaccination. Our study also demonstrates that weakly positive HBsAg results often do not reflect actual HBV infection, underscoring the importance of confirmatory testing. This study also emphasizes that vaccination-induced HBsAg positives occur most commonly in hemodialysis patients.
【 授权许可】
2012 Rysgaard et al.; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150113172430654.pdf | 327KB | download | |
Figure 3. | 52KB | Image | download |
Figure 2. | 62KB | Image | download |
Figure 1. | 64KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
【 参考文献 】
- [1]Liaw YF, Chu CM: Hepatitis B virus infection. Lancet 2009, 373:582-592.
- [2]Dienstag JL: Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
- [3]Fabrizi F, Messa P, Martin P: Hepatitis B virus infection and the dialysis patient. Semin Dial 2008, 21:440-446.
- [4]Janzen L, Minuk GY, Fast M, Bernstein KN: Vaccine-induced hepatitis B surface antigen positivity in adult hemodialysis patients: incidental and surveillance data. J Am Soc Nephrol 1996, 7:1228-1234.
- [5]Kloster B, Kramer R, Eastlund T, Grossman B, Zarvan B: Hepatitis B surface antigenemia in blood donors following vaccination. Transfusion 1995, 35:475-477.
- [6]Weintraub Z, Khamaysi N, Elena H, Gershtein V, Orenstein L, Lahat N: Transient surface antigenemia in newborn infants vaccinated with Engerix B: occurrence and duration. Pediatr Infect Dis J 1994, 13:931-933.
- [7]Bernstein SR, Krieger P, Puppala BL, Costello M: Incidence and duration of hepatitis B surface antigenemia after neonatal hepatitis B immunization. J Pediatr 1994, 125:621-622.
- [8]Challapalli M, Slosar M, Vasa R, Cunningham DG: Brief surface antigenemia in newborn infants vaccinated with hepatitis B vaccine. Pediatr Infect Dis J 1993, 12:878-879.
- [9]Challapalli M, Naidu V, Cunningham DG: Hepatitis B surface antigenemia in a newborn infant after vaccination. Pediatr Infect Dis J 1993, 12:408-409.
- [10]Dealler SF, Anson J: HBsAg vaccinaemia in a newborn. Med Lab Sci 1992, 49:343.
- [11]Ly D, Yee HF Jr, Brezina M, Martin P, Gitnick G, Saab S: Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization. Am J Gastroenterol 2002, 97:138-141.
- [12]Esparza N, Moreno A, Toledo A, Suria S, Rossique P, Garcia-Canton C, Palomar O, Checa MD: Spurious hepatitis B surface antigen detection in adult haemodialysis patients following vaccination. Nephrol Dial Transplant 1999, 14:794.
- [13]Riley S, Tong CY, Rutherford PA: Spurious hepatitis B surface antigen detection in a haemodialysis patient. Nephrol Dial Transplant 1998, 13:1897-1898.
- [14]Seed CR, Lee JF, Maloney R, Di Rosso A, Cobain TJ: Hepatitis B surface antigenemia in blood donors after vaccination. Transfusion 1996, 36:386.
- [15]Wang JT, Wang TH, Sheu JC, Shih LN, Lin JT, Chen DS: Detection of hepatitis B virus DNA by polymerase chain reaction in plasma of volunteer blood donors negative for hepatitis B surface antigen. J Infect Dis 1991, 163:397-399.
- [16]Vanacker A, Vandewiele I, Verbanck J, Schepkens H, De Schoenmakere G, De Laere E, Maes B: Transiently positive hepatitis B surface antigen after vaccination with the new hepatitis B vaccine HBV-AS04. Am J Kidney Dis 2008, 52:1028-1029.
- [17]Sharma S, Saini N, Arora L, Chawla Y, Duseja A: Prolonged Hepatitis B surface antigen positivity in Hepatitis B vaccine recipients. Dig Liver Dis 2006, 38:860-861.
- [18]De Schryver A, De Gendt K, Francois G, Van Damme P, Meheus A: Hepatitis B surface antigenaemia following vaccination with a combined vaccine against hepatitis A and B. J Viral Hepat 2004, 11:88-90.